Arthritis :: Bone erosion reduced by denosumab in phase 2 trial
Treatment with denosumab 60 mg and 180 mg, with background methotrexate, reduces the progression of bone erosion according to results of a 227 patient-Phase II trial presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.